Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers
Human Genome Sciences, Inc. today reported that clinical and preclinical evidence continues to emerge demonstrating that its TRAIL
